As of 2024-12-15, the EV/EBITDA ratio of Denali Therapeutics Inc (DNLI) is -6.49. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. DNLI's latest enterprise value is 3,220.84 mil USD. DNLI's TTM EBITDA according to its financial statements is -496.00 mil USD. Dividing these 2 quantities gives us the above DNLI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 15.1x | 13.8x |
| Forward P/E multiples | 15.2x - 21.1x | 15.5x |
| Fair Price | (51.79) - (51.31) | (49.90) |
| Upside | -325.5% - -323.4% | -317.2% |
| Date | EV/EBITDA |
| 2024-12-12 | -6.64 |
| 2024-12-11 | -6.75 |
| 2024-12-10 | -6.93 |
| 2024-12-09 | -7.07 |
| 2024-12-06 | -7.05 |
| 2024-12-05 | -6.60 |
| 2024-12-04 | -6.71 |
| 2024-12-03 | -6.76 |
| 2024-12-02 | -7.27 |
| 2024-11-29 | -7.08 |
| 2024-11-27 | -7.13 |
| 2024-11-26 | -6.99 |
| 2024-11-25 | -6.94 |
| 2024-11-22 | -6.99 |
| 2024-11-21 | -6.86 |
| 2024-11-20 | -6.91 |
| 2024-11-19 | -6.89 |
| 2024-11-18 | -6.84 |
| 2024-11-15 | -7.10 |
| 2024-11-14 | -8.08 |
| 2024-11-13 | -8.43 |
| 2024-11-12 | -8.50 |
| 2024-11-11 | -8.99 |
| 2024-11-08 | -8.93 |
| 2024-11-07 | -8.42 |
| 2024-11-06 | -8.40 |
| 2024-11-05 | -7.85 |
| 2024-11-04 | -7.72 |
| 2024-11-01 | -7.68 |
| 2024-10-31 | -7.36 |
| 2024-10-30 | -7.62 |
| 2024-10-29 | -7.80 |
| 2024-10-28 | -7.89 |
| 2024-10-25 | -7.42 |
| 2024-10-24 | -7.50 |
| 2024-10-23 | -7.40 |
| 2024-10-22 | -7.46 |
| 2024-10-21 | -7.48 |
| 2024-10-18 | -7.83 |
| 2024-10-17 | -7.78 |
| 2024-10-16 | -7.85 |
| 2024-10-15 | -7.62 |
| 2024-10-14 | -7.61 |
| 2024-10-11 | -7.95 |
| 2024-10-10 | -7.30 |
| 2024-10-09 | -7.52 |
| 2024-10-08 | -7.58 |
| 2024-10-07 | -7.55 |
| 2024-10-04 | -8.14 |
| 2024-10-03 | -8.02 |